Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Obliterative bronchiolitis
ADR ID BADD_A03104
ADR Hierarchy
22      Respiratory, thoracic and mediastinal disorders
22.03      Bronchial disorders (excl neoplasms)
22.03.01      Bronchospasm and obstruction
22.03.01.012      Obliterative bronchiolitis
10      Immune system disorders
10.02      Immune disorders NEC
10.02.01      Immune and associated conditions NEC
10.02.01.096      Obliterative bronchiolitis
12      Injury, poisoning and procedural complications
12.02      Procedural related injuries and complications NEC
12.02.09      Transplantation complications
12.02.09.036      Obliterative bronchiolitis
Description Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA. | A form that is characterized by partial or complete obstruction of bronchiolar lumens resulting from chronic bronchiolar inflammation, scarring, and smooth muscle hypertrophy. | A form that is histologically characterized by intraluminal polyps of organizing connective tissue. [MeSH]
MedDRA Code 10029888
MeSH ID D001989
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Obliterative bronchiolitis | Bronchiolitis obliterans | Bronchiolitis Obliterans | Constrictive Bronchiolitis | Bronchiolitides, Constrictive | Bronchiolitis, Constrictive | Constrictive Bronchiolitides | Bronchiolitis, Exudative | Bronchiolitides, Exudative | Exudative Bronchiolitides | Exudative Bronchiolitis | Bronchiolitis, Proliferative | Bronchiolitides, Proliferative | Proliferative Bronchiolitides | Proliferative Bronchiolitis
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00047Afatinib0.000168%
BADD_D00115Amiodarone--
BADD_D00116Amiodarone hydrochloride--
BADD_D00194Azacitidine0.000112%
BADD_D00318Busulfan--
BADD_D00405Ceftriaxone0.004457%
BADD_D00407Cefuroxime0.000215%
BADD_D00480Clarithromycin0.000223%
BADD_D00549Cyclophosphamide--
BADD_D00551Cyclosporine0.000166%
BADD_D00560Cytarabine0.000112%
BADD_D00800Erlotinib--
BADD_D01119Ibrutinib0.000112%
BADD_D01136Imatinib0.000168%
BADD_D01167Interferon alfa-2b--
BADD_D01243Lamotrigine0.000166%
BADD_D01257Letrozole0.000263%
BADD_D01397Mesalamine--
BADD_D01409Methane--
BADD_D01418Methotrexate0.000398%
BADD_D01420Methoxsalen0.000521%
BADD_D01433Methylprednisolone0.000032%
BADD_D01709Penicillamine--
BADD_D01765Phenytoin0.000382%
BADD_D01834Prednisone0.000009%
BADD_D01953Rituximab--
BADD_D01978Ruxolitinib0.000137%
BADD_D02026Simvastatin0.000007%
BADD_D02028Sirolimus--
BADD_D02105Tacrolimus0.000891%
The 1th Page    1 2    Next   Last    Total 2 Pages